Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: Pooled analysis of individual patient data

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 4, 2013, Pages 397-406

  Temmerman, F ^a   Gevers, T ^b   Ho, T A ^c   Vanslembrouck, R ^a   Coudyzer, W ^a   Van Pelt, J ^a   Bammens, B ^a   Pirson, Y ^c   Drenth, J P ^b   Nevens, F ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; PLACEBO;

ABDOMINAL CRAMP; ADULT; ARTICLE; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; HAIR LOSS; HUMAN; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; STEATORRHEA; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CYSTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; ROC CURVE; SOMATOSTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880258947     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12384     Document Type: Article

References (21)

1. Temmerman F, Missiaen L, Bammens B, et al,. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 2011; 34: 702-13.
2. Bae KT, Zhu F, Chapman AB, et al,. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006; 1: 64-9.
3. Hoevenaren IA, Wester R, Schrier RW, et al,. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int 2008; 28: 264-70.
4. van Keimpema L, de Koning DB, van Hoek B, et al,. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int 2011; 31: 92-8.
5. Schnelldorfer T, Torres VE, Zakaria S, Rosen CB, Nagorney DM,. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2009; 250: 112-8.
6. Pirenne J, Aerts R, Yoong K, et al,. Liver transplantation for polycystic liver disease. Liver Transpl 2001; 7: 238-45.
7. van Keimpema L, Nevens F, Adam R, et al,. Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int 2011; 24: 1239-45.
8. Masyuk TV, Masyuk AI, Torres VE, et al,. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 2007; 132: 1104-16.
9. van Keimpema L, Nevens F, Vanslembrouck R, et al,. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661-8.
10. Hogan MC, Masyuk TV, Page LJ, et al,. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052-61.
11. Ruggenenti P, Remuzzi A, Ondei P, et al,. Safety and efficacy of longacting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 206-16.
12. Caroli A, Antiga L, Cafaro M, et al,. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5: 783-9.
13. Khan MS, El-Khouly F, Davies P, et al,. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther 2011; 34: 235-42.
14. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, 2006. Available at: http://ctep.cancer.gov. Accessed March 31, 2003.
15. Kilbride HS, Stevens PE, Eaglestone G, et al,. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. Am J Kidney Dis 2013; 61: 57-61.
16. Hogan MC, Masyuk TV, Page L, et al,. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27: 3532-9.
17. Chrispijn M, Nevens F, Gevers TJ, et al,. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012; 35: 266-74.
18. Schmidt A, Pleiner J, Schaller G, et al,. Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. Kidney Int 2002; 61: 1788-93.
19. Chapman AB, Bost JE, Torres VE, et al,. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012; 7: 479-86.
20. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M,. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol 2008; 68: 473-80.
21. De Martino MC, Hofland LJ, Lamberts SW,. Somatostatin and somatostatin receptors: from basic concepts to clinical applications. Prog Brain Res 2010; 182: 255-80.